Join Humacyte for a virtual key opinion leader (KOL) event featuring Prabir Roy-Chaudhury MD, PhD, FASN (University of North Carolina (UNC) Kidney Center, Salisbury VA Medical Center), and Mohamad A. Hussain, MD, PhD, RPVI, FAHA, FRCSC, FACS (Brigham & Women’s Hospital, Center for Surgery and Public Health, Harvard Medical School), who will join company management to discuss the unmet need and current treatment landscape for hemodialysis patients with End-Stage Renal Disease (ESRD).

The event will provide an overview of the Company’s investigational Acellular Tissue Engineered Vessels (ATEV.) The current standard of care for providing AV access involves connecting the patient’s artery with a vein, known as an arteriovenous fistula or AV fistula (AVF). Humacyte’s ATEV is designed to provide an alternative to the current standard of care for hemodialysis patients with ESRD, as AVFs can take weeks or months to mature and become usable for hemodialysis, and in many patients fail to mature at all. One Phase 3 trial has already been completed showing the superiority of the ATEV in AV Access compared to autologous AV fistula. Company management will also review the ongoing V012 Phase 3 trial in hemodialysis for which interim top-line results are expected this quarter.

A live question and answer session will follow the formal presentations.